Background {#Sec1}
==========

The use of isavuconazole is approved for the management of invasive aspergillosis and mucormycosis, only in adults, as no paediatric pharmacology studies have been reported to date \[[@CR1]\]. Very few paediatric cases have been published concerning the use of isavuconazole \[[@CR2], [@CR3]\]. Amphotericin B and posaconazole are the only antifungal molecules recommended in mucormycosis in patients with haematological malignancies \[[@CR4]\]. However, posaconazole is not yet approved in paediatric population, and the availability of IV and new per os formulations is recent. Moreover adverse effects, especially nephrotoxicity, related to the use of amphotericin B, liposomal formulation included, could be problematic. In children, therapeutic options are limited and the use of other antifungal molecules active on Mucorales becomes necessary.

Case presentation {#Sec2}
-----------------

At the end of 2015, a 3-year-old girl, with B-cell acute lymphocytic leukaemia with TEL-AML1 fusion and profound neutropenia, was started treatment with EORTC 58081 protocol (NCT01185886), medium risk AR1. After 19 days of prednisolone (60 mg/m^2^/day), two doses of vincristine (1.5 mg/m^2^), one dose of daunorubicin (30 mg/m^2^) and one dose of asparaginase (10,000 IU/m^2^), she developed febrile neutropenia with digestive problems. Procalcitonin and serum C-reactive protein (CRP) levels were 1.85 ng/mL and 91 mg/L, respectively. Chemotherapy was discontinued and antibiotherapy was started with ceftriaxone. Due to persistence of fever, ceftriaxone was switched on Day 3 to piperacillin-tazobactam for 14 days and amikacin for 3 days. At that time, neutrophil count was 0.5 × 10^9^/L. Increasing CRP (350 mg/L) prompted the addition of caspofungin on Day 6 (70 mg/m^2^ day 1, followed by 50 mg/m^2^/day) following a local protocol established according to international guidelines \[[@CR5]\]. Twice weekly screening for serum mannan, galactomannan (Platelia™; Bio-Rad Laboratories) and (1,3)-β-D-glucan (Fungitell™; Associates of Cape Cod, Inc.) remained negative. On Day 10 of fever, a chest computed tomography (CT) scan showed condensation in the left lower lobe associated with right pleural effusion evocative of invasive aspergillosis. Treatment with intravenous voriconazole was started (9 mg/kg bid day 1, then 8 mg/kg bid) and caspofungin was stopped. An abdominal ultrasound showed bilateral nephromegaly. Direct microscopic examination, culture, galactomannan detection and *Aspergillus* q-PCR in bronchoalveolar lavage were negative. All blood cultures remained sterile.

On Day 21 of fever, neutrophil count was 11.2 × 10^9^/L. Fundoscopy was performed because of a reduction in visual acuity, revealing multiple subretinal foci suspected to be fungal in origin. Direct microscopy of vitreous humour revealed large, aseptate, ribbon-like hyphae. Among the different mycological techniques used, only Mucorales q-PCR was positive for *Lichtheimia* spp. (Cq 31) in vitreous humour, but was negative in serum. Magnetic resonance imaging (MRI) showed two abscess-like cerebral lesions and confirmed the kidney infiltration (Fig. [1](#Fig1){ref-type="fig"}a). A diagnosis of disseminated mucormycosis was established.Fig. 1**a** Plasma trough concentration of isavuconazole after intravenous (IV) or oral dosing (arrows indicate times of pharmacokinetic study days). In parallel, cerebral MRIs on Day 21 of fever and after 6 months of antifungal treatment showing regression of a ring-enhanced cerebral lesion (from 5.5 cm in diameter to 3.2 cm) in the right frontal parietal region. **b** Pharmacokinetic profiles of isavuconazole. Plasma concentrations of isavuconazole during 24 h following dosing at day 7 (90 mg/d, IV), and during 12 h following dosing day 24 (90 mg bid, IV) and day 44 (100 mg bid, oral). (bid, twice a day; IV, intravenous; L-AmB, liposomal amphotericin B; po, per os)

Despite limited experience in children, voriconazole was switched to isavuconazole (ISAV) (compassionate off-label use) instead of liposomal amphotericin B (L-AmB), because of renal impairment. Each dose (70 mg every 8 h for 48 h, then 70 mg/day IV) was infused over 1 h. Plasma drug monitoring was implemented from Day 3 after ISAV introduction (AISAVI) and was repeated regularly up to Day 150 (Fig. [1](#Fig1){ref-type="fig"}a). Considering a target trough plasma level (TPL) of 2000--4000 ng/mL (approximate average adult TPL observed in Phase 3 studies) \[[@CR6], [@CR7]\], low TPL on Day 5 AISAVI prompted an increase in dose to 90 mg/day. A pharmacokinetic profile (Fig. [1](#Fig1){ref-type="fig"}b) obtained on Day 7 AISAVI showed that TPL decreased to 1110 ng/mL at 24 h. The ISAV dosage was changed to 90 mg twice daily and L-AmB (10 mg/kg/day) was added despite renal impairment because of the cerebral lesions and difficulties in achieving the ISAV TPL target. The TPL target was reached on Day 17 AISAVI and levels were stable by Day 24. In order to facilitate home nursing care, the route of administration was changed to capsules (100 mg bid). Due to difficulties in swallowing, the capsules were opened and the contents dissolved in an acidic beverage. After 1 week, the mixture was introduced via a nasogastric tube because of vomiting. Median TPL was 4890 ng/mL from Day 66 AISAVI and remained stable over time, while the maximum concentration was obtained between 1 or 2 h after administration, with values varying between 4200 and 4690 ng/ml (Fig. [1](#Fig1){ref-type="fig"}b).

With the exception of slight nausea/vomiting during the first 2 months after initiation, no adverse effects were noted with ISAV, and liver enzymes were in the range of normal values observed in healthy subjects. The patient was in complete cytological and molecular remission and was chemotherapy-free for 7 months, until her leukaemia relapsed at 8 months. The patient was treated with the first-line CAALL-F01 protocol (NCT02716233), medium risk, and was in complete remission 4 months after relapse. Because of the risk of drug interactions, L-AmB (7 mg/kg/day) was continued alone for 4 months and was then replaced with ISAV (50 mg twice daily). Antifungal treatment was maintained during maintenance chemotherapy. The size of the cerebral abscesses decreased between the first and last MRI (at 16 months) from 55 × 37 and 45 × 38.4 mm to 23.5 × 18 and 17 × 17 mm with persistence of hypometabolism on a fluorodeoxyglucose-positron emission tomography scan (FDG PET/CT). Renal insufficiency was stable with clearance of 78 ml/min/m^2^ according to the Schwartz formula. The loss of left-sided vision was irreversible. After 24 months of treatment, the patient was still alive without further damage. The treatment timeline is shown in the Table [1](#Tab1){ref-type="table"}.Table 1Timeline of eventsClinical featuresBiology resultsAntimicrobial therapyD-19Start of chemotherapyNeutropeniaD0Febrile neutropeniaHigh level of CRP and PCTAntibiotherapy introductionCeftriaxone 100 mg/kg/dD3Persistence of feverRising of CRP and PCT ratesAntibiotherapy switchTazobactam Piperacillin 400 mg/kg/d\
AmikacineD6Persistence of feverAdding antifungal therapyCaspofungin 70 mg/m^2^ day 1, then 50 mg/m^2^/dD10Abnormal chest CT scan and abdominal ultra-soundAntifungal combined therapyAdding voriconazole 9 mg/kg bid day 1, then 8 mg/kg bid IVD16Negative BALWithdrawal Antibiotherapy and caspofunginD21Positive FundoscopyVoriconazole intravitreal injection 50 μg/mlD24Abnormal brain MRI\
Initiation of TDM on D27Switch antifungal therapyIsavuconazole 70 mg every 8 h for 48 h, then 70 mg/d IVD31Isavuconazole 90 mg/d IVD37Antifungal combined therapyIsavuconazole 90 mg bid IV\
L-AmB 10 mg/kg/dD39Fever resolutionD58Isavuconazole 100 mg bid *p.o*D63TPL steady stateM6Regression of lesions on imageryM8Leukaemia relapseWithdrawal isavuconazoleL-AmB 7 mg/kg/dM12Complete remissionSwitch antifungal therapyIsavuconazole 50 mg bid *p.o*M16Regression of lesions on imagery*BAL* bronchoalveolar lavage, bid, twice a day, *CRP* C-Reactive protein, *d* day, *IV* intra-venous, *L-AmB* liposomal amphotericin B, *PCT* procalcitonin, *p.o* per os, *TDM* therapeutic drug monitoring, *TPL* trough plasma level

Discussion and conclusions {#Sec3}
==========================

The incidence of mucormycosis in Europe is increasing \[[@CR8]--[@CR10]\]. Haematological malignancy is the prominent underlying disease, accounting for 32--38% of cases \[[@CR10]\]. Diagnosis of mucormycosis depends on a combination of clinical, radiological and mycological criteria, and is often missed or delayed. Our patient was diagnosed 25 days after the onset of fever. The time between the first symptoms and diagnosis ranges from 0 to 30 weeks \[[@CR11]\]. In our patient, disseminated mucormycosis appeared as an early complication of leukaemia (19 days after the start of chemotherapy). However, her fungal infection may have begun to develop before the diagnosis of leukaemia, probably in relation to the initial profound neutropenia. She rapidly presented with cerebral, ocular, pulmonary, muscular and renal lesions. Although surgery may improve survival \[[@CR12], [@CR13]\], the discovery of cerebral and disseminated lesions in this patient prevented surgical intervention. L-AmB is the most effective antifungal agent against Mucorales with doses up to 10 mg/kg \[[@CR12], [@CR14]\]. More recently, two azoles with potent activity against Mucorales have been developed as alternatives to L-AmB: posaconazole and ISAV \[[@CR6], [@CR12]\]. In animal models, azoles penetrate brain tissue well \[[@CR15]\]. However, neither posaconazole nor ISAV drug are currently approved for paediatric use. Only an oral suspension posaconazole has been tested in children and this resulted in high inter- and intra-patient variability in serum concentrations \[[@CR16]\]. An intravenous formulation was not available in France at that time. ECIL-6 guidelines recommend posaconazole with grade CIII as an alternative treatment if AmB formulations are contraindicated \[[@CR4]\]. Recently, two trials (VITAL, SECURE) have been reported which led to the recent indication, in adults, of ISAV use in cases where L-AmB is inappropriate \[[@CR17]\]. In view of the renal impairment in our patient, ISAV was considered as a treatment option \[[@CR18]\].

According to a paediatric epidemiological study based on two large international registries of mucormycosis, mortality rates range from 41.3 to 66.6% in children suffering from malignancies \[[@CR13]\]. Although dissemination was one of two significant factors influencing mortality, our patient is still alive 24 months after the diagnosis of mucormycosis. However, an assessment of the specific contribution of ISAV to this favourable outcome remains difficult. Indeed, the early termination of chemotherapy contributing to faster aplasia recovery, the prolonged remission of leukaemia without chemotherapy and the concomitant use of L-AmB at the start of antifungal therapy may all have played an important role in the outcome. However, it should be emphasized that the fungal lesions continued to regress under ISAV alone. Moreover, tolerance of ISAV was good and this case provides interesting information about ISAV pharmacokinetics and alternative routes of administration in the paediatric population.

Recently, the use of ISAV in three young children, between 4.5 and 7 years of age having developed mucormycosis, has been reported \[[@CR2], [@CR3]\]. For two of them, the initial dose of ISAV was lower than that in adult, 80 and 100 mg/day, respectively. The remaining one received the adult dosage (200 mg/day). In the present case, we started with the recommended dose of 70 mg/day after a loading dose. Because of the absence of data in children, initial estimation of dose was obtained via extrapolation approach based on pharmacokinetic-pharmacodynamic modelling and calculation based on body surface area. Altogether, pharmacokinetics studies obtained from these patients suggest that a lower dosage of ISAV is not appropriate for the management of paediatric patients. Indeed, higher drug clearance rate and shorter half- life of ISAV in children as compared with adults may explain lower trough levels obtained in these three cases \[[@CR2]\]. The final dosage for two paediatric cases was 200 mg/day, the 7-year-old girl received a higher dose increased to 2 × 200 mg/day. In the three previous cases, while the infection was progressing despite surgery/debridement and lipid formulations of AmB, the clinical states improved with the addition of ISAV as salvage therapy. No side effects were reported in all of these paediatric cases, which underline the safety of isavuconazole in this population.

Although more evidence is needed to support its paediatric use, this case offers new perspectives on the use of ISAV. Due to the current lack of an established paediatric dose, therapeutic drug monitoring of ISAV must be performed to guide therapy.

AISAVI

:   After isavuconazole introduction

CRP

:   C-reactive protein

FDG PET/CT

:   Fluorodeoxyglucose-positron emission tomography scan

ISAV

:   Isavuconazole

L-AmB

:   Liposomal amphotericin B

MRI

:   Magnetic resonance imaging

TPL

:   Trough plasma level

Not applicable.

Funding {#FPar1}
=======

This work was supported by internal funding "Fonds d'aide à l'émergence et à l'excellence du CHRU de Lille-Bonus H".

Availability of data and materials {#FPar2}
==================================

Not applicable

MC, BB, SL, PN, NF, FL, EAB, FB, FM and BS were involved in the patient care and the management of her fungal disease. MC, BB, SL, FD and BS wrote the manuscript. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

Basilea Pharmaceutica International Ltd., provided the medication for compassionate use in the context of a Temporary Authorization for Use which was granted by the French National Agency for Medicines and Health Products Safety. Its authorization has been obtained after a multidisciplinary consultation meeting.

In this context, the parents of the child were informed and gave their consent for compassionate use of isavuconazole.

Consent for publication {#FPar4}
=======================

Written informed consent for publication of their clinical details and/or clinical images was obtained from the parent of the patient. A copy of the consent form is available for review by the Editor of this journal.

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
